Drug data last refreshed 3h ago · AI intelligence enriched 2w ago
ZEFAZONE (cefmetazole sodium) is a second-generation cephalosporin antibiotic administered by injection for bacterial infections. It works by inhibiting bacterial cell wall synthesis, making it effective against gram-positive and gram-negative organisms. This product addresses serious infections requiring parenteral therapy in hospital and surgical settings.
With LOE approaching and moderate competitive pressure (30%), the brand team is likely in consolidation mode, focusing on managed care and hospital formulary retention rather than expansion.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on ZEFAZONE offers limited career growth potential given its LOE status and zero linked job openings; positions focus on defensive commercial strategy and operational efficiency rather than innovation or expansion. This product is better suited for early-career professionals seeking stable institutional knowledge or those transitioning into generic/mature product management.
Worked on ZEFAZONE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.